{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:56:16Z","timestamp":1765230976116},"reference-count":30,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014598","name":"MannKind Corporation","doi-asserted-by":"crossref","award":["7916"],"award-info":[{"award-number":["7916"]}],"id":[{"id":"10.13039\/100014598","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Rose Pharma A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Regulatory Peptides"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.regpep.2012.08.009","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T23:46:29Z","timestamp":1346802389000},"page":"71-76","source":"Crossref","is-referenced-by-count":10,"title":["Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat"],"prefix":"10.1016","volume":"179","author":[{"given":"P.M.","family":"Hellstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Smithson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Stowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Damico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Leone-Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.regpep.2012.08.009_bb0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1463-1326.2008.00853.x","article-title":"GLP-1: physiological effects and potential therapeutic applications","volume":"10","author":"Aaboe","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.regpep.2012.08.009_bb0010","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.regpep.2012.08.009_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.molmed.2008.01.003","article-title":"Glucagon-like peptide-1, glucose homeostasis and diabetes","volume":"14","author":"Holst","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.regpep.2012.08.009_bb0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2982.2007.01079.x","article-title":"GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome","volume":"20","author":"Hellstr\u00f6m","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.regpep.2012.08.009_bb0025","first-page":"R910","article-title":"GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans","volume":"277","author":"N\u00e4slund","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.regpep.2012.08.009_bb0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-201X.1996.42256000.x","article-title":"Distribution of GLP-1 and PACAP receptors in human tissues","volume":"157","author":"Wei","year":"1996","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.regpep.2012.08.009_bb0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2036.2008.03870.x","article-title":"Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study","volume":"29","author":"Hellstr\u00f6m","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.regpep.2012.08.009_bb0040","first-page":"G920","article-title":"Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms","volume":"273","author":"Imeryuz","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.regpep.2012.08.009_bb0045","doi-asserted-by":"crossref","first-page":"978-e78","DOI":"10.1111\/j.1365-2982.2009.01317.x","article-title":"Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat","volume":"21","author":"Bucinskaite","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.regpep.2012.08.009_bb0050","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.40.5.597","article-title":"The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7\u201336 amide on gastric acid secretion in humans depends on an intact vagal innervation","volume":"40","author":"Wettergren","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.regpep.2012.08.009_bb0055","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1365-2982.2010.01554.x","article-title":"Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis","volume":"22","author":"Edholm","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.regpep.2012.08.009_bb0060","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1023\/A:1026678925120","article-title":"Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms","volume":"43","author":"Tolessa","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.regpep.2012.08.009_bb0065","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1172\/JCI942","article-title":"Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin","volume":"102","author":"Tolessa","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.regpep.2012.08.009_bb0070","first-page":"A-227","article-title":"Patient willingness to use ROSE-010: a subcutaneous (SC) GLP-1 analogue for IBS pain episodes","volume":"138","author":"Spiegel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.regpep.2012.08.009_bb0075","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1463-1326.2009.01096.x","article-title":"Evaluation of novel particles as an inhalation system for GLP-1","volume":"11","author":"Leone-Bay","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.regpep.2012.08.009_bb0080","series-title":"Pulmonary drug delivery \u2013 simplified","first-page":"18","author":"Leone-Bay","year":"2011"},{"key":"10.1016\/j.regpep.2012.08.009_bb0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-201X.1996.524292000.x","article-title":"Characteristics of fasting and fed myoelectric activity in rat small intestine: evaluation by computer analysis","volume":"158","author":"Br\u00e4nstr\u00f6m","year":"1996","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.regpep.2012.08.009_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.regpep.2009.04.004","article-title":"GLP-1: broadening the incretin concept to involve gut motility","volume":"156","author":"Hellstr\u00f6m","year":"2009","journal-title":"Regul Pept"},{"key":"10.1016\/j.regpep.2012.08.009_bb0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/B978-0-12-381517-0.00012-6","article-title":"Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility","volume":"84","author":"Hellstr\u00f6m","year":"2010","journal-title":"Vitam Horm"},{"key":"10.1016\/j.regpep.2012.08.009_bb0100","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7\u201336)amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regpep.2012.08.009_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0969-8051(98)00121-8","article-title":"In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7\u201336) amide in the rat studied by gamma camera","volume":"26","author":"Hassan","year":"1999","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.regpep.2012.08.009_bb0110","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1210\/jc.2002-021873","article-title":"Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regpep.2012.08.009_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/11536700-000000000-00000","article-title":"Technosphere insulin: an inhaled prandial insulin product","volume":"24","author":"Neumiller","year":"2010","journal-title":"BioDrugs"},{"key":"10.1016\/j.regpep.2012.08.009_bb0120","series-title":"Innovation in drug delivery by inhalation","first-page":"4","author":"Leone-Bay","year":"2010"},{"key":"10.1016\/j.regpep.2012.08.009_bb0125","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/193229680900300320","article-title":"Technosphere insulin: defining the role of Technosphere particles at the cellular level","volume":"3","author":"Angelo","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.regpep.2012.08.009_bb0130","doi-asserted-by":"crossref","first-page":"G120","DOI":"10.1152\/ajpgi.00076.2012","article-title":"Effect of a glucagon-like peptide I analog, ROSE-010, on gastrointestinal motor functions in females with constipation-predominant irritable bowel syndrome","volume":"303","author":"Camilleri","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.regpep.2012.08.009_bb0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/clpt.2010.85","article-title":"Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes","volume":"88","author":"Marino","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.regpep.2012.08.009_bb0140","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.regpep.2012.08.009_bb0145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2337\/diabetes.49.4.611","article-title":"Effect of glucagon-like peptide 1(7\u201336) amide on glucose effectiveness and insulin action in people with type 2 diabetes","volume":"49","author":"Vella","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2012.08.009_bb0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"}],"container-title":["Regulatory Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016701151200225X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016701151200225X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:10:01Z","timestamp":1588828201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016701151200225X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":30,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S016701151200225X"],"URL":"https:\/\/doi.org\/10.1016\/j.regpep.2012.08.009","relation":{},"ISSN":["0167-0115"],"issn-type":[{"value":"0167-0115","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}